Is 7-OH Banned? DEA Schedule I Status and What Happens August 5, 2026

Over the past few weeks, one question has come up more than any other in the botanical products space: is 7-OH banned? The short answer is that a federal action is underway, it is specific in scope, and it has a date attached to it. The longer answer requires understanding what the Drug Enforcement Administration actually filed, what "temporary scheduling" means as a legal mechanism, and where the boundaries of the action sit.

This article walks through the documents in plain English. It is written for consumers and retailers who want to understand the timeline without wading through the full Federal Register text. Nothing here is legal advice, and the rules that apply to any particular product depend on that product's specific composition and on the law of the state where it is sold.

What the DEA Filed on July 1, 2026

On July 1, 2026, the DEA announced that it had filed two Notices of Intent to temporarily place 7-hydroxymitragynine (commonly shortened to 7-OH) above a specified threshold into Schedule I of the Controlled Substances Act.

The filings did not stop at 7-OH alone. Three related compounds were named alongside it:

• Mitragynine pseudoindoxyl (MP)
• Dihydro-7-hydroxymitragynine (MGM-15)
• 9-fluoro-7-hydroxymitragynine (MGM-16)

The inclusion of MGM-15 and MGM-16 is worth pausing on. These are not compounds a consumer would encounter by drinking traditional leaf tea. They are laboratory-derived analogs, and their presence in the filing signals that the agency is looking at a category of concentrated and modified molecules rather than at a plant.

The Notices of Intent were published in the Federal Register on July 6, 2026. Publication is the step that starts the clock.

The August 5, 2026 Timeline

Here is the sequence, laid out simply:

Two details in that table are easy to misread. First, "on or after August 5" is not the same as "on August 5." A Notice of Intent establishes the earliest date the order can publish; it does not guarantee that date. Second, the order takes effect on the day it publishes, not thirty or sixty days later. There is no built-in grace period between publication and effect.

So as of today, July 25, 2026, the accurate statement is: 7-OH above the specified threshold is not yet a Schedule I controlled substance at the federal level, and the notice period for that placement is running.

What "Temporary Scheduling" Actually Means

Temporary scheduling is a specific authority Congress gave the DEA, and it works differently from the ordinary rulemaking most people picture.

Normal scheduling is a slow, deliberative process. It involves a formal scientific and medical evaluation, a recommendation from the Department of Health and Human Services, a proposed rule, a public comment period, and a final rule. It can take years.

Temporary scheduling is designed to move faster when an agency concludes that immediate action is warranted. The agency publishes a Notice of Intent, waits a minimum period, and then may publish the order. The placement lasts two years and can be extended by one additional year while the agency works through the permanent process. The Congressional Research Service has published a legal sidebar that walks through the statutory mechanics for readers who want the full framework.

A few practical consequences follow from the "temporary" label:

• Temporary does not mean provisional in effect. While in force, a temporarily scheduled substance carries the same federal Schedule I consequences as a permanently scheduled one.
• Temporary does mean time-limited on paper. The two-year window is real, and the placement lapses if the agency does not act further.
• It is a federal action. States have their own controlled substance schedules, and some already regulate these compounds independently. Federal scheduling does not replace state law, and it does not answer what is or is not permitted in any particular state.

What the Action Covers, and What It Does Not

This is the part most often lost in headlines. The filing is not a ban on kratom leaf.

The action is aimed at 7-OH above a specified threshold. Ordinary botanical kratom leaf naturally contains 7-OH only in trace amounts, well below the threshold the DEA identified. Material in that trace range is outside the scope of the scheduling action as filed.

What falls inside the scope is the category of enhanced, concentrated, synthetic, and semi-synthetic 7-OH articles: extracts and concentrates where 7-OH has been isolated or elevated, processed edibles, pressed tablets, and shots formulated to specific 7-OH content. Those are the products the threshold is built to capture.

The threshold itself has two prongs and deserves its own treatment. We have broken it down with worked arithmetic in The DEA's 7-OH Threshold Explained.

What This Means for the Shelf

For retailers and consumers, the practical picture between now and the effective date is one of transition. Distributors are reviewing certificates of analysis. Retailers are reassessing which products in their case fall on which side of the threshold. Manufacturers of concentrated 7-OH articles face a decision point.

Meanwhile, many consumers are exploring the broader botanical category and asking a simpler question: what else is out there that has nothing to do with this molecule at all? Interest in kratom-free botanicals has grown noticeably over the past month. Cat's Claw (Uncaria tomentosa) is one such botanical, an entirely separate plant from a different genus and continent, with no mitragynine or 7-OH content of any kind. If you are new to it, our introduction to Cat's Claw covers the basics, and every batch we carry is backed by third-party testing you can review on our certificate of analysis page. You can browse the full Cat's Claw collection as well.

Frequently Asked Questions

Is 7-OH illegal right now?

As of July 25, 2026, the temporary scheduling order has not published. The Notices of Intent were filed July 1 and published July 6; the order may publish on or after August 5, 2026 and takes effect the day it publishes. Separately, some states already regulate these compounds under their own laws, so the federal timeline is not the whole picture. Check your state and local law.

Does this ban all kratom?

No. The action targets 7-OH above a specified threshold, plus three named analogs. Ordinary botanical leaf containing only trace naturally-occurring 7-OH below the threshold is not within the scope of the filing as written.

How long does the temporary placement last?

Two years from the date the order takes effect. Federal law allows the agency to extend that period while it works through permanent scheduling.

Why were MGM-15 and MGM-16 included?

Both are laboratory-derived analogs rather than compounds found meaningfully in leaf. Including them in the same filing addresses closely related molecules at the same time rather than in sequence.

Where can I read the primary documents?

The DEA press release is here, the Federal Register notice is 91 FR 40917, Docket No. DEA-1570, and the Congressional Research Service legal sidebar is here. Reading the sources directly is always better than relying on a summary, including this one.

These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For adults 21+. Consult a qualified healthcare professional before use.